Trial
NCT04796922
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Incyte Corporation
Collaborators
—
Condition
Follicular Lymphoma ( FL)
Intervention
parsaclisib
Why stopped
This study was withdrawn due to a business decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-18